Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine

Journal of Infectious Diseases

Volumn 184, Issue 6, 2001, Pages 781-784

  Picard, Véronique ^a   Angelini, Emmanuelle ^e   Maillard, Anne ^a   Race, Esther ^c   Clavel, François ^d   Chêne, Geneviève ^e   Ferchal, François ^a   Molina, Jean Michel ^b  

^a Virology   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Viralliance   (France)

^d BICHAT HOSPITAL   (France)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS RECOMBINANT;

ADULT; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; POINT MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

EID: 0035884247     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/323088     Document Type: Article

References (15)

1. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
2. The ALBI Trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus
3. Susceptibility of HIV-1 isolates to zidovudine: Correlation between widely applicable culture test and PCR analysis
4. Loss of viral fitness associated with multiple gag and gag-pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
5. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
6. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
7. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy
8. Potential mechanism for sustained anti-retroviral efficacy of AZT-3TC combination therapy
9. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase
10. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome
11. Stavudine resistance: An update on susceptibility following prolonged therapy
12. Occurrence of thymidine-associated mutations in naive patients treated more than 6 months by stavudine/lamivudine bi-therapy combination and tri-therapy including stavudine/didanosine or stavudine/lamivudine
13. Presence of thymidine-associated mutations and response to d4T, abacavir and ddI in the control arm of the NARVAL ANRS 088 Trial
14. Genotypic predictors of virologic response to stavudine after zidovudine monotherapy (ACTG 302)
15. A new mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β2′, 3′-dideoxy-3′-thiacytidine